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Abstract Sarcoidosis is a rare but important cause of
neurological morbidity, and neurological symptoms often
herald the diagnosis. Our understanding of neurosarcoido-
sis has evolved from early descriptions of a uveoparotid
fever to include presentations involving every part of the
neural axis. The diagnosis should be suspected in patients
with sarcoidosis who develop new neurological symptoms,
those presenting with syndromes highly suggestive of
neurosarcoidosis, or neuro-inflammatory disease where
more common causes have been excluded. Investigation
should look for evidence of neuro-inflammation, best
achieved by contrast-enhanced brain magnetic resonance
imaging and cerebrospinal fluid analysis. Evidence of
sarcoidosis outside the nervous system should be sought in
search of tissue for biopsy. Skin lesions should be identi-
fied and biopsies taken. Chest radiography including high-
resolution computed tomography is often informative. In
difficult cases, fluorodeoxyglucose positron emission
tomography and gallium-67 imaging may identify sub-
clinical disease and a target for biopsy. Symptomatic
patients should be treated with corticosteroids, and if
clinically indicated other immunosuppressants such as
hydroxychloroquine, azathioprine, cyclophosphamide or
methotrexate should be added. Anti-tumour necrosis factor
alpha therapies may be considered in refractory disease but
caution should be exercised as there is evidence to suggest
they may unmask disease.




Neurosarcoidosis (NS) is a rare neuro-inflammatory dis-
order with protean manifestations which presents a diag-
nostic challenge to general physicians and neurologists
alike. In 2007, we highlighted how case series continued to
refine our understanding, and that anti-tumour necrosis
factor alpha (TNF-a) therapies may hold promise as ster-
oid-sparing agents in difficult disease [1, 2]. Nine years on,
we provide a clinically focused update on the management
of NS, guided by knowledge from new case series,
refinements in diagnostic criteria and further reports on
anti-TNF-a and other immunosuppressive therapies.
Definition and epidemiology
Sarcoidosis is a multi-organ granulomatous disease of
unknown aetiology, and is characterised pathologically by
multiple non-caseating granulomata in the absence of a
defined infective or toxic trigger [3]. In a US based study,
incidence (in person-years) was estimated at 10.9/100,000
in Americans of European ancestry and 35.5/100,000 in
those of African ancestry [4].
Neurosarcoidosis, the involvement of the nervous sys-
tem by sarcoid granulomata, is uncommon, occurring
symptomatically in 5–16% of patients with sarcoidosis
[5–8]. Our regional hospital-based study of patients in
South West England and South Wales estimated a preva-
lence of 1/100,000 [9]. Across two case series, we found a
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mean age at diagnosis of 39 years and similar prevalence in
females and males (47 vs. 53% across 98 patients) [2, 9]. A
significant proportion of NS is subclinical as confirmed by
autopsy studies; one showed nervous system involvement
in 14% of those with sarcoidosis [10]; another found only
in 50% was NS diagnosed in life [11].
Background
The first case description of sarcoidosis is attributed to
Hutchinson in 1869 when he described a coal-wharf worker
with skin changes in his hands and legs [12]. The first account
of a neurological syndrome attributable to sarcoidosiswas by
Heerfordt, who in 1909 reported three males with uveitis,
parotid enlargement and fever; two had a facial nerve palsy
[13]. Kveim’s observation that sarcoid lymph node tissue
generated an immunological response when injected intra-
dermally in patients with sarcoidosis, provided evidence for
a non-tubercular basis to the uveoparotid syndrome [14].
Siltzbach and colleagues subjected this to clinical trial and
confirmed the Kveim–Siltzbach test highly specific (95%)
and sensitive (79%) for sarcoidosis [15].
Case series with heterogeneous definitions of NS
expanded our understanding of NS beyond Heerfordt’s
uveoparotid fever [16]. Zajicek et al.’s diagnostic criteria
provided a much needed framework for case definition,
separating definite disease (with a positive biopsy from the
nervous system) from probable and possible disease [2].
Refinements of these criteria have since been proposed,
guided by emerging technologies such as thoracic high-
resolution computed tomography (HRCT), and immuno-
histochemistry for CD4:CD8 lymphocyte ratios in bron-
cho-alveolar lavage (BAL) specimen [17].
Natural history
The natural history of NS is poorly characterised due to its
rarity, variability in diagnostic criteria and the frequent use
of corticosteroid or immunosuppressive therapy. Large
case series show neurological symptoms and signs herald
the diagnosis of sarcoidosis in 31–71% [2, 6, 9, 18–20]. In
those with established sarcoidosis, NS can develop years
after disease onset [6, 9, 18].
NS may be monophasic, relapsing or chronic and out-
comes relate to disease phenotype. Intracranial or spinal
mass lesions often relapse on corticosteroids following
dose reduction [9]. Optic neuritis tends also to have a
relapsing phenotype [2]. Facial mononeuropathies on the
other hand often remit, carrying a better prognosis [6, 21].
Myopathy and peripheral neuropathy are less common and
can be chronic [22].
Diagnosis
When should neurosarcoidosis be suspected?
From a Bayesian perspective, there are two clinical sce-
narios in which it would be reasonable to suspect NS.
These are: (1) the development of a neurological problem
in a patient known to have sarcoidosis and (2) a patient
presenting with a neurological syndrome ‘typical’ for NS.
Patients with cryptogenic neuro-inflammatory disease in
whom common mimics have been excluded should also be
investigated for NS.
In the patient with systemic sarcoidosis who develops
new neurological symptoms and signs, the likelihood of
any such neurological presentation being due to sar-
coidosis is high—with the proviso that individuals who
have received immunosuppression as part of their pre-
vious sarcoid treatment may be at greater risk of CNS
infections, which, therefore, must be rigorously exclu-
ded. The likelihood becomes higher still once the
problem is characterised as being neuro-inflammatory.
Such reasoning is captured in Zajicek’s criteria for
probable NS [2].
Similarly, should any neurological syndrome be
uncommon in general, but common in NS, its emergence
would support a search for sarcoidosis as the basis for
disease. A wide range of presentations are reported, but of
these: the uveoparotid syndrome and cranial oligoneu-
ropathy (for example a bilateral facial neuropathy) most
readily meet these conditions (see Table 1), while long
lesions of the cervical or thoracic spine, a cauda equina
syndrome, or pituitary and/or hypothalamic involvement,
with or without obstructive hydrocephalus, are also char-
acteristic of CNS sarcoidosis.
Cryptogenic neuro-inflammatory disease is a not infre-
quent problem for the practising neurologist. In the
authors’ view, following the exclusion of common infec-
tive and auto-immune causes, NS should be considered.
Longitudinally extensive myelitis where serology for neu-
romyelitis optica is negative, is now recognised to often be
secondary to NS [23].
How should the diagnosis of neurosarcoidosis be
established?
A definite diagnosis, on the basis of nervous system
biopsy is preferred, but is not always practicable
depending on the site of disease [2]. The diagnostic
process for probable NS should otherwise involve con-
firming a neuro-inflammatory basis to disease and inves-
tigating for sarcoidosis.
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Table 1 Clinical presentations and their characteristics as reported in NS
Clinical presentation Characteristics in NS
Aseptic meningitis [2, 6, 9, 18–22, 24] Mostly this is asymptomatic and inferred from CSF abnormalities.
Where patients are symptomatic, the presentation is usually subacute
or chronic
Typical CSF finds are: pleocytosis (\220 cells/mm3) with a
lymphocytic predominance and/or raised protein (\4.3 g/l). Reduced
CSF glucose is also reported
Conus or cauda equina syndrome [9, 19, 43] This may be of acute or subacute onset. CSF and imaging abnormalities
usually confirm a neuro-inflammatory basis
Cranial neuropathy [2, 6, 8, 18–22, 24] This is the most frequently reported manifestation of NS. Any cranial
nerve can be involved but facial and optic nerves are most frequently
affected
Facial nerve palsies often spontaneously remit and carry a good
prognosis
Cranial oligoneuropathy or polyneuropathy (e.g. bilateral facial nerve
palsy) is suggestive of NS
Optic nerve involvement may have a more difficult disease course with
refractory disease and relapse on corticosteroid dose reduction
A pharynx, soft palate and vocal cord syndrome from glossopharyngeal
and vagus nerve involvement is recognised
Basal meningitis may be the pathophysiological substrate of cranial
neuropathies
Focal neurology, multifocal neurology or diffuse encephalopathy due
to parenchymal lesions of the brain or brainstem [2, 8, 9, 18–22, 44]
Lesions may be multiple and often enhance. Biopsy of mass lesions is
recommended for a definitive diagnosis
Behaviour change, confusional states and psychosis are reported
Hypothamic and pituitary dysfunction
[2, 6, 8, 9, 20, 22, 28, 29, 44–46]
Usually of insidious onset, due to suprasellar inflammatory lesions. The
most eminent symptoms are bitemporal visual failure, polydipsia and
polyuria (diabetes insipidus), and galactorrhoea
Symptoms may arise from hypothalamic dysfunction, hypopituitarism
or compression of the optic chiasm by mass effect
An aseptic meningitis is often seen
Myopathy [6, 19, 20, 22, 38] Usually asymptomatic. Where symptomatic, this presents as proximal
weakness. Biopsy is reported to have a high diagnostic yield
Peripheral polyneuropathy [6, 8, 19, 20, 22, 24] Pure sensory and mixed neuropathies are reported. Mononeuritis
multiplex is also described
Raised intracranial pressure [2, 6, 9, 19–22] Patients usually present non-specifically with a headache and visual
disturbance. Clinical signs may include papilloedema
CSF and imaging show evidence of active inflammation, including
meningeal enhancement and ventriculitis
Hydrocephalus may develop and may require surgical management
Seizures [8, 9, 18, 21, 22, 38] Can be a feature of cortical or subcortical disease
Spinal cord syndromes and radiculitis [2, 6, 9, 20, 22–24] Mass lesions and inflammatory lesions are reported. A Guillain–Barre´-
like syndrome is occasionally described
In longitudinally extensive myelitis where aquaporin antibodies are
negative, NS should be considered
Uveoparotid fever [13] Uveitis, parotid gland swelling, fever and facial nerve palsy constitute
this syndrome which is pathognomonic of sarcoidosis
CSF often shows evidence of an aseptic meningitis
Vascular syndromes [8, 20, 47–49] Ischaemic stroke, haemorrhagic stroke and dural venous sinus
thrombosis are infrequently reported
Perivascular inflammation has been demonstrated in biopsy and post-
mortem specimen
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Confirming a neuro-inflammatory basis to disease
Enhancement on contrast-enhanced magnetic resonance
imaging (MRI), as evidence of break-down of the blood–
brain barrier, is a highly sensitive marker of neuro-in-
flammatory disease and is recommended in the investiga-
tion of NS. Where this is not practicable, contrast-enhanced
computed tomography (CT) is an alternative. Cere-
brospinal fluid (CSF) examination is helpful as constituents
are often abnormal, with lymphocytic pleocytosis (in
31–83%) and elevated protein (in 40–83%) being typical;
low glucose is occasionally identified, and an unmatched
oligoclonal band pattern is often found (in 27–37%)
[2, 6, 9, 18, 19, 24].
Symptomatic muscle involvement should lead to tar-
geted biopsy, though success has been reported with blind
biopsy in asymptomatic patients [25]. Imaging is less likely
to demonstrate involvement of peripheral nerves, but
electrophysiology may provide supporting evidence.
Where tissue is amenable to biopsy and the risk–benefit
balance is favourable, nervous system tissue biopsy is
recommended to confirm the diagnosis.
Investigating for sarcoidosis
Sarcoidosis should be diagnosed on the basis of non-
caseating granulomata in the absence of other granulomatous
disease. There is a predilection for intrathoracic, skin and
ocular tissues which guides investigation [26]. Chest radio-
graphy is often abnormal (in 31–82%), typically showing
bihilar lymphadenopathy [2, 6, 9, 18, 20, 21, 23, 24, 27–29].
HRCT is more sensitive, and may identify areas for BAL or
endobronchial ultrasound (EBUS)-guided biopsy [3, 30].
A BAL CD4:CD8 lymphocyte ratio of[3.5:1 is a well-
validated marker, highly specific for sarcoidosis [31, 32].
Mediastinoscopy may permit biopsy of involved intratho-
racic lymph nodes not accessible by EBUS. Where skin
disease is present, dermatological review and biopsy is rec-
ommended.Ophthalmological assessment, though helpful in
confirming ocular involvement, is less helpful for identifying
tissue to biopsy.
Whole body fluorodeoxyglucose positron emission
tomography (FDG-PET) and gallium-67 imaging are
helpful investigations which identify asymptomatic
involved tissue, may confirm a typical disease pattern and
suggest a site for biopsy [33].
The Kveim–Siltzbach test has fallen into disuse. Safety
concerns with regard transmissible infectious disease and
exhaustion of existing antigen underlie this decline. Other
investigations such as CSF or serum angiotensin converting
enzyme, though often suggested as part of the work-up of
NS, are insufficiently specific to be of diagnostic value
[34, 35].
Treatment
What treatment should be initiated?
The natural history of NS is poorly defined, but sponta-
neous remission is recognised. Response to corticosteroids
is the norm, but long-term outcomes are variable. Most are
established on corticosteroids (e.g. prednisolone at
0.5–1 mg/kg) and 40–82% show sustained improvement or
stability [2, 6, 18, 20, 29]. Case-mix differences most likely
underlie differences in outcomes. In patients with a partial,
or non-sustained response to steroids, or in whom long-
term therapy is required, the usual practise is to establish a
second-line immunosuppressant such as hydroxychloro-
quine, azathioprine, cyclophosphamide or methotrexate
[1]. The successful use of cranial irradiation has been
reported for difficult disease [36].
As macrophage-derived TNF-a plays a critical role in
granuloma formation, anti-TNF-a therapies are hypothe-
sised to be efficacious in NS. Successful outcomes in
corticosteroid-refractory NS have been reported for inflix-
imab (with 34 such reports as of 2014 [37]), and with
adalimumab [38, 39]. Notwithstanding the risk of bias in
retrospective case reports, the temporal correlation between
administration and improvement, and the occurrence of
sustained remission support a therapeutic effect [37, 40].
We did not find any reports of etanercept as a successful
therapy in NS. There are sporadic reports of the use of
other monoclonal biologic therapies in treatment-refractory
NS.
A recently emerging potential complication of anti-
TNF-a therapies has been the occurrence of new onset
sarcoidosis-like disease in patients receiving these agents
for other indications. As of 2012, 37 such cases had been
described with 22 (60%) attributable to etanercept, sug-
gesting an asymmetric class effect. Though paradoxical
and unexpected, the close temporal association of sar-
coidosis with anti-TNF-a therapies, resolution on cessa-
tion, and re-manifestation on repeat challenge support an
aetiological role [41]—whilst challenging the previously
accepted but arguably simplistic mechanism of action in
treating sarcoidosis of blocking TNF-a.
How should disease be monitored?
No reliable biomarkers have yet been identified to monitor
disease activity in NS. The authors would advocate an
individualised approach, guided by the neurological system
involved. Visual acuity and colour vision testing may for
example guide the monitoring of optic neuritis and con-
trast-enhanced MRI may support the monitoring of
inflammatory lesions. PET-CT may play a role [42].
1026 J Neurol (2017) 264:1023–1028
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Conclusion
Case series continue to broaden the phenotype of NS,
reinforcing the need for a systematic approach to diagnosis
and management. Adverse findings with anti-TNF-a ther-
apies suggest they should be used with caution in NS.
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